InvestorsHub Logo
Followers 51
Posts 9111
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Sunday, 12/18/2022 1:30:38 AM

Sunday, December 18, 2022 1:30:38 AM

Post# of 13489
Patients treated with a combination of mRNA-4157 plus Keytruda were 44% less likely to die or see their tumors return compared to patients who had Keytruda on its own. If these results can be repeated in a larger population, mRNA-4157 could become a new cancer drug in just a few years$$$$$$$$

Recent results suggest the company's cancer vaccine candidate can succeed where others have failed.


relax$


https://www.fool.com/investing/2022/12/15/is-moderna-a-good-stock-to-buy-right-now/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News